------------------------
OMB Approval
------------------------
UNITED STATES OMB Number: 3235-0060
SECURITIES AND EXCHANGE COMMISSION Expires: April 30, 2009
Washington, D.C. 20549 Estimated average burden
hours per response..38.0
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2007
-------------------------------
POSSIS MEDICAL, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Minnesota 0-944 41-0783184
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
9055 Evergreen Boulevard NW, Minneapolis, MN 55433-8003
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 763-780-4555
------------------------------
Not Applicable
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 - Regulation FD Disclosure
On March 12, 2007, Possis Medical, Inc., announced the full market
release of its new AngioJet(R) Ultra Thrombectomy System. The
next-generation Ultra System, which was approved by the U.S. Food and
Drug Administration (FDA) in December 2006 for blood clot removal
(thrombectomy), is now available for sale to hospitals and physicians
throughout the United States. A copy of the press release is furnished
as Exhibit 99.1 to this Report.
Item 9.01 Financial Statements and Exhibits
[c] Exhibits
99.1 Press Release, dated March 12, 2007, issued by Possis Medical, Inc.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Possis Medical, Inc.
--------------------
(Registrant)
Date: March 12, 2007
--------------
By: /s/ Jules L. Fisher
-----------------------------------------------------
Jules L. Fisher
Vice President, Finance and Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press Release, dated March 12, 2007, issued by
Possis Medical, Inc.